Compare Stocks: ZVSA, ONCO, CRIS, and GNPX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRIS Curis	$1.35 -1.5%	$3.94	$1.30 ▼ $39.00	$2.82M	3.01	344,934 shs	96,906 shs
GNPX Genprex	$3.50 +2.3%	$6.95	$3.37 ▼ $1,210.00	$2.87M	-0.94	316,071 shs	37,209 shs
ONCO Onconetix	$1.02 +38.0%	$0.84	$0.59 ▼ $209.50	$4.47M	2.68	193,319 shs	6.29 million shs
ZVSA ZyVersa Therapeutics	$0.10 +3.8%	$0.11	$0.08 ▼ $0.30	$817K	0.87	33,728 shs	2,528 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRIS Curis	-1.46%	-9.40%	-70.33%	-85.74%	-96.08%
GNPX Genprex	+2.34%	-4.63%	-21.17%	-75.40%	-98.06%
ONCO Onconetix	+38.02%	+66.59%	+1.49%	-0.97%	-99.31%
ZVSA ZyVersa Therapeutics	+3.83%	-1.90%	-0.39%	-48.50%	-20.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRIS Curis	$1.35 -1.5%	$3.94	$1.30 ▼ $39.00	$2.82M	3.01	344,934 shs	96,906 shs
GNPX Genprex	$3.50 +2.3%	$6.95	$3.37 ▼ $1,210.00	$2.87M	-0.94	316,071 shs	37,209 shs
ONCO Onconetix	$1.02 +38.0%	$0.84	$0.59 ▼ $209.50	$4.47M	2.68	193,319 shs	6.29 million shs
ZVSA ZyVersa Therapeutics	$0.10 +3.8%	$0.11	$0.08 ▼ $0.30	$817K	0.87	33,728 shs	2,528 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRIS Curis	-1.46%	-9.40%	-70.33%	-85.74%	-96.08%
GNPX Genprex	+2.34%	-4.63%	-21.17%	-75.40%	-98.06%
ONCO Onconetix	+38.02%	+66.59%	+1.49%	-0.97%	-99.31%
ZVSA ZyVersa Therapeutics	+3.83%	-1.90%	-0.39%	-48.50%	-20.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRIS Curis	1.67	Reduce	$43.00	3,085.19% Upside
GNPX Genprex	1.00	Sell	N/A	N/A
ONCO Onconetix	1.00	Sell	N/A	N/A
ZVSA ZyVersa Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZVSA, ONCO, CRIS, and GNPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/17/2026	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/11/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/24/2026	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $43.00
7/17/2026	CRIS Curis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GNPX Genprex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/13/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
6/29/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
6/11/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRIS Curis	$9.44M	0.30	N/A	N/A	$2.25 per share	0.60
GNPX Genprex	N/A	N/A	N/A	N/A	$18.05 per share	N/A
ONCO Onconetix	$810K	5.52	N/A	N/A	$3.41 per share	0.30
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	$3.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRIS Curis	-$7.58M	-$14.22	N/A	N/A	N/A	-80.29%	-2,365.94%	-200.88%	11/5/2026 (Estimated)
GNPX Genprex	-$16.23M	-$133.36	N/A	N/A	N/A	N/A	-163.12%	-128.98%	N/A
ONCO Onconetix	-$14.03M	$248.12	0.00	N/A	N/A	-1,575.89%	-91.95%	-53.76%	11/12/2026 (Estimated)
ZVSA ZyVersa Therapeutics	-$9.41M	-$0.83	N/A	N/A	N/A	N/A	-109.54%	-43.95%	11/18/2026 (Estimated)

Latest ZVSA, ONCO, CRIS, and GNPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CRIS Curis	-$6.95	-$4.02	+$2.93	-$4.02	$1.00 million	N/A
8/14/2026	Q2 2026	GNPX Genprex	N/A	-$9.40	N/A	-$9.40	N/A	N/A
8/13/2026	Q2 2026	ONCO Onconetix	-$4,505.00	-$1.28	+$4,503.72	-$1.28	$0.02 million	$0.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRIS Curis	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	N/A
ONCO Onconetix	N/A	N/A	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRIS Curis	N/A	0.49	0.49
GNPX Genprex	N/A	6.76	6.76
ONCO Onconetix	N/A	2.21	2.14
ZVSA ZyVersa Therapeutics	N/A	0.18	0.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRIS Curis	29.97%
GNPX Genprex	14.05%
ONCO Onconetix	23.89%
ZVSA ZyVersa Therapeutics	3.91%

Insider Ownership

Company	Insider Ownership
CRIS Curis	5.78%
GNPX Genprex	0.25%
ONCO Onconetix	0.27%
ZVSA ZyVersa Therapeutics	0.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRIS Curis	60	2.09 million	1.97 million	No Data
GNPX Genprex	20	820,000	818,000	No Data
ONCO Onconetix	12	4.38 million	4.37 million	N/A
ZVSA ZyVersa Therapeutics	2	7.94 million	4.86 million	Not Optionable

ZVSA, ONCO, CRIS, and GNPX Headlines

Recent News About These Companies

ZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc. Corporate Event Calendar | OTC:ZVSA

July 27, 2026 | benzinga.com

ZyVersa Therapeutics Transitions to OTC Pink Market

July 17, 2026 | tipranks.com

ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 13, 2026 | globenewswire.com

ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

March 31, 2026 | globenewswire.com

Zyversa Therapeutics Faces Financial Challenges Amid Drug Development

November 20, 2025 | msn.com

ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

November 19, 2025 | globenewswire.com

ZyVersa Therapeutics Delays 10-Q Filing

November 14, 2025 | tipranks.com

Zyversa Therapeutics’ Promising Phase 2a Study on DKD Treatment

October 28, 2025 | msn.com

ZyVersa Therapeutics Faces Nasdaq Delisting Notice

September 18, 2025 | tipranks.com

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term ...

September 10, 2025 | markets.businessinsider.com

ZyVersa Therapeutics Highlights Role of Inflammasomes in Type 2 Diabetes and Cardiovascular Complications with Promising Data on IC 100

September 10, 2025 | quiverquant.comQ

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

September 10, 2025 | globenewswire.com

ZyVersa Therapeutics highlights lipidomic data in Alport Syndrome, DKD

September 3, 2025 | msn.com

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease ...

September 3, 2025 | finance.yahoo.com

ZyVersa Therapeutics Initiates Phase 2a Clinical Trial for Cholesterol Efflux Mediator™ VAR 200 in Diabetic Kidney Disease Patients

September 3, 2025 | quiverquant.comQ

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

September 3, 2025 | globenewswire.com

ZyVersa Therapeutics Reports Financial Challenges Amid Nasdaq Delisting

August 20, 2025 | msn.com

ZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last year

August 14, 2025 | msn.com

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address ...

August 14, 2025 | bakersfield.comB

ZyVersa Therapeutics highlights data on role of lipotoxicity in DKD

August 14, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZVSA, ONCO, CRIS, and GNPX Company Descriptions

Curis NASDAQ:CRIS

$1.35 -0.02 (-1.46%)

As of 09/4/2026 04:00 PM Eastern

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Genprex NASDAQ:GNPX

$3.50 +0.08 (+2.34%)

As of 09/4/2026 04:00 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Onconetix NASDAQ:ONCO

$1.02 +0.28 (+38.02%)

As of 09/4/2026 04:00 PM Eastern

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

ZyVersa Therapeutics NASDAQ:ZVSA

$0.10 +0.00 (+3.83%)

As of 09/4/2026 01:42 PM Eastern

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZVSA, ONCO, CRIS, and GNPX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZVSA, ONCO, CRIS, and GNPX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZVSA, ONCO, CRIS, and GNPX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZVSA, ONCO, CRIS, and GNPX Company Descriptions

Curis NASDAQ:CRIS

Genprex NASDAQ:GNPX

Onconetix NASDAQ:ONCO

ZyVersa Therapeutics NASDAQ:ZVSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZVSA, ONCO, CRIS, and GNPX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZVSA, ONCO, CRIS, and GNPX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZVSA, ONCO, CRIS, and GNPX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZVSA, ONCO, CRIS, and GNPX Company Descriptions

Curis NASDAQ:CRIS

Genprex NASDAQ:GNPX

Onconetix NASDAQ:ONCO

ZyVersa Therapeutics NASDAQ:ZVSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools